Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Au-TMP
- Development stage
- Phase 1
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Nanoparticles → Drug Delivery Systems, Peptides
- Administration
- Intratumoral
01
Overview
Au-TMP is an experimental nanoparticle-based radiosensitizer consisting of gold (Au) nanoparticles conjugated with a tumor-homing peptide (TMP), specifically the TKPRP sequence. Developed by West China Hospital of Sichuan University, the gold nanoparticle core functions as a high-atomic-number (high-Z) material that enhances the efficacy of radiotherapy by increasing the local absorption of ionizing radiation and promoting the generation of reactive oxygen species (ROS). This process leads to targeted DNA damage and apoptosis within tumor cells. The TMP peptide (TKPRP) specifically targets Neuropilin-1 (NRP-1), a receptor frequently overexpressed in melanoma and tumor-associated vasculature, facilitating selective accumulation and cellular internalization of the nanoparticles. Au-TMP is administered via intratumoral injection and is currently being evaluated in Phase I clinical trials for the treatment of advanced melanoma in combination with radiotherapy and the anti-PD-1 antibody toripalimab.
- Other names
- Au-TMP nanoparticlesTKPRP-modified gold nanoparticles
02
Targets
DNANRP1 (Neuropilin-1)
Beyond the preview
Go deeper on Au-TMP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Au-TMP.